Assessing Legislation’s Impact on Drug Development: Medicare Price Controls and March-In Guidelines ByJustin Leventhal January 3, 2024January 3, 2024
Economic Standard: March-In Guidelines Are Marching in the Wrong Direction ByJustin Leventhal December 20, 2023February 28, 2024
The Economic Standard: Regulatory Roadblocks to Quitting Smoking ByJustin Leventhal November 14, 2023February 28, 2024
COPPA 2.0 and KOSA Misdiagnose the Cause of Mental Health Crisis ByTrey Price October 19, 2023October 19, 2023
Price Controls Aren’t the Cure for High Medicare Drug Prices ByJustin Leventhal September 11, 2023February 28, 2024
Arguments for Harsh Vaping Regulations Are Just Smoke and Mirrors ByJustin Leventhal August 24, 2023February 28, 2024
Sweden’s Harm Reduction Miracle Can Be Replicated in the U.S. ByNate Scherer July 17, 2023February 28, 2024
Report Refutes Claims Vaping is Gateway to Youth Smoking ByNate Scherer July 6, 2023February 28, 2024
